Clinical trials of new drugs for skin diseases under development have achieved milestones, and Tekoro has bucked the trend to win tens of millions of Series A+ financing

On January 13, Jiaxing Tekoro Biotechnology Co.
, Ltd.
(hereinafter referred to as "Tekoro"), which focuses on the research and development of new skin drugs, announced that it has recently completed a series A+ financing
of tens of millions of yuan.
Thanks to the capital market's favor and high recognition of the company's hair and eczema dermatitis clinical pipeline, the company has obtained the support and empowerment
of Chengdu Biocity No.
1 Equity Investment Fund and Chengdu High-tech New Economy Venture Capital Co.
, Ltd.
in this round of financing.

"Seek life in difficult situations and seek development in adversity!" Dr.
Wang Zengquan, founder and CEO of Tekoro Biologics, said that it is based on this concept that Tekoro Biologics has maintained the company's efficient and stable drug research and development characteristics under the background of the repeated new crown epidemic and global economic slowdown in 2022, steadily promoted the progress of clinical pipeline drug research and development, and actively introduced new fund partners
.
The company's clinical trial of new drugs has achieved milestone progress, and the A+ round of financing has been successfully completed
.

TDM-105795, a blockbuster small molecule topical drug for the treatment of androgenetic alopecia (AGA), successfully completed the phase I clinical study at the end of December 2022, and is expected to start phase II clinical trial
in mid-March 2023 。 In addition, TDM-180935, a topical drug for atopic dermatitis (AD), successfully obtained FDA Phase I clinical approval in August 2022, and the project has officially entered Phase I clinical trials in the United States (Gov.
Trial Identifier: NCT05525468）
。

According to reports, TDM-105795 is a first-in-class small molecule thyroxine receptor agonist independently developed by Turkoro for AGA, and the phase I clinical trial is divided into I(Gov.
Trial Identifier: NCT05244980) and Ib (Gov.
Trial Identifier: NCT05244980) was conducted
in two clinical phases.
The Phase I clinical trial was successfully completed in the United States at the end of December 2022 and reached all clinical endpoints
.
The results of the phase I trial met expectations for both the safety of the drug and the exploration of drug dose
.
The results of the phase I clinical trial showed that TDM-105795 in each drug dose group had no skin irritation, no systemic adverse events including cardiac side effects, did not affect the level of thyroid hormones in the body, and TDM-105795
was almost undetectable in plasma.
TDM-105795 has a high safety profile for external use
.
This provides a good basis
for the upcoming Phase II clinical trial for efficacy.

In addition to new drugs entering clinical trials, Tekoro's pipeline also includes TDM-004, a topical drug for psoriasis, which is undergoing preclinical safety evaluation testing; TDM-003, an oral drug for systemic lupus erythematosus, is already at the CMC stage
.
In addition, Tekoro and the Department of Dermatology at the University of Michigan are conducting a drug discovery phase study for skin scarring and are currently optimizing the lead compound
.

According to public information, Tekoro is a small molecule drug research and development innovative enterprise focusing on skin diseases, and completed a series A financing
of tens of millions of yuan led by CDH VGC in 2021 and co-invested by Haisong Medical Venture Capital and Leading Capital.
The company aims to build the world's leading professional new drug research and development company
in the field of dermatology through independent research and development of first-in-class global new drugs for major skin-related diseases.

In the face of the severe cold of the capital market in 2022, Tekoro seized the opportunity to seek development in terms of company construction, actively cooperated with Chengdu High-tech Zone, introduced new fund partners, and paved the way for the industrialization and commercialization of products in the next 5 years
.
The company's A+ round of financing has received strong support from the Chengdu High-tech Zone government and related industry funds, and the company has obtained tens of millions of A+ round financing
.

According to Dr.
Wang Zengquan, in the future, Tekoro will also steadily promote the research and development of clinical pipeline drugs in the treatment of hair loss, atopic dermatitis, psoriasis, lupus erythematosus, scarring and
other diseases.
After the hair loss and dermatitis projects have entered the clinical trial stage, the company will also promote its topical drugs for the treatment of psoriasis into the first clinical phase
in 2023.
"The company will seek cooperation with excellent industrial partners in an open and active cooperation
mode in the process of clinical development, industrialization and commercialization.
"